ArticleScientific reports2025
O-GlcNAcylation of DDB1 at Ser-764 by OGT promotes cancer cell stemness in colorectal cancer through increased polyubiquitination of p53.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The role of the WD40-repeat protein family in cancer.Molecular cancer · 2026Review
- O-glycosylation in Cancer: Emerging Paradigms and Prospects for Precision Oncology.International journal of biological sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Several ubiquitin E3 ligases, including MDM2, COP1, HUWE1, and CUL4A-DDB1, regulate the stability of the p53 protein, which is crucial for maintaining cell survival, promoting apoptosis, facilitating DNA repair, and preventing the stemness of cancer cells. The CUL4A-DDB1 complex is recognized as one of the non-canonical pathways that control p53 stability. However, the role of DDB1 O-GlcNAcylation has not been studied until now. Here, we present new evidence that DDB1 glycosylation mainly decreases p53 protein levels by promoting the formation of the CUL4A-DDB1-p53 complex. DDB1 is highly expressed in colorectal cancer (CRC) and plays a crucial role in supporting the functions of cancer stem cells (CSCs). Our data show that DDB1 is O-GlcNAcylated by OGT, with Ser-764 as the primary glycosylation site. Notably, the glycosylation-defective DDB1 mutant (Ser764A) reduces its interaction with CUL4A and p53, resulting in decreased p53 ubiquitination. These results suggest an inverse relationship between DDB1 glycosylation levels and p53 stability. The CSC-defective traits in DDB1-deficient CRC cells were rescued by p53 deficiency but not by its overexpression, indicating that the CUL4A-DDB1-mediated regulation of p53 stability may control cancer stem-like properties in CRC. In summary, our findings emphasize DDB1 as a key regulator of colorectal cancer stemness and p53 stability through its O-GlcNAcylation at Ser-764, which enhances the E3 ligase activity of the CUL4-DDB1 complex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.